ResMed Inc.
RMDHealthcareNASDAQMedical Instruments & Supplies · Last scanned Sep 8, 2026
Scan Results
Daily timeframeResMed Inc. engages in the digital health and cloud-connected medical devices business in the United States and internationally. Valued at $32.94B, RMD is a large-cap name in its sector. It operates in two segments, Sleep and Breathing Health, and Residential Care Software.
Market Cap
$32.94B
Beta
0.77
P/E (TTM)
21.87
P/E (Fwd)
17.28
EPS (TTM)
$10.44
EPS (Fwd)
$13.21
ROE
24.3%
ROA
14.0%
Cash
$1.47B
Total Debt
$825.9M
Free CF
$939.2M
52W Change
-18.2%
Annual Financials
Cash vs Debt
Where RMD stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, RMD finished 4.78% above its 150-day moving average ($220.33) and 1.57% above its 200-day moving average ($227.31). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is RMD overbought or oversold?
At the September 3, 2026 close, RMD's RSI(14) was 55.7, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $1.47B in cash comfortably exceeding the $825.9M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company generates $939.2M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at 24.3%, which is strong for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Return on assets of 14.0% further supports the picture of efficient asset utilization. Revenue has grown from $4.22B (2023) to $5.65B (2026), reflecting a 34% increase over the period.
Investors considering ResMed Inc. should weigh the typical risks associated with RMD's sector, size, and financial profile against their own risk tolerance and investment objectives. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for ResMed Inc. and its sector.